Trials / Completed
CompletedNCT02983617
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib (formerly GS-4059) and entospletinib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic leukemia (CLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirabrutinib | Administered orally once daily |
| DRUG | Entospletinib | Administered orally once daily |
| DRUG | Obinutuzumab | Administered intravenously |
Timeline
- Start date
- 2017-04-06
- Primary completion
- 2019-02-20
- Completion
- 2020-10-01
- First posted
- 2016-12-06
- Last updated
- 2021-12-21
- Results posted
- 2020-02-28
Locations
15 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02983617. Inclusion in this directory is not an endorsement.